h/m P53 shRNA Lentivirus

Background

p53, encoded by TP53, is a transcription factor and one of the most important tumor suppressors in the cell. In response to DNA damage, oncogene activation, and other stresses, p53 is stabilized and activates programs of cell cycle arrest, DNA repair, senescence, and apoptosis to prevent the propagation of damaged cells. p53 also regulates metabolism, autophagy, and ferroptosis. TP53 is the most frequently mutated gene in human cancer, and loss of p53 function permits genomic instability and uncontrolled proliferation. Because of its central role in guarding genome integrity, p53 is a major focus of cancer research.

Product Description & Applications

The h/m P53 shRNA Lentivirus delivers validated short hairpin RNA targeting human and mouse TP53 from a third-generation, self-inactivating lentiviral backbone. shRNA expression is driven by a U6 promoter, with a co-expressed fluorescent reporter (GFP or RFP) and antibiotic selection marker. VSV-G pseudotyping enables broad tropism across primary, suspension, and cryopreserved cells, and each shRNA is validated for at least 70% p53 knockdown by a fluorescence-based method.

High-titer particles are ultra-purified by PEG precipitation and sucrose gradient centrifugation. A shRNA set option provides a mix of two independent validated shRNAs plus a scrambled control. Applications include loss-of-function studies of tumor suppression, the DNA damage response, cell cycle control, and apoptosis.

About This Product

This validated shRNA lentivirus targeting TP53 (NCBI Accession: NM_000546.6) delivers a 19–20 bp shRNA from a third-generation, self-inactivating lentiviral backbone. Expression is driven from a U6 Pol III promoter, with a constitutively expressed fluorescent reporter (GFP, GFP/Luc, RFP, RFP/Luc) and antibiotic selection marker (Puromycin, Blasticidin) co-expressed from the same vector. VSV-G pseudotyping enables broad cell tropism, including primary, suspension, and cryopreserved cell types.

Knockdown is validated using a proprietary bicistronic fluorescence assay in which the target mRNA is co-expressed fused to RFP alongside the shRNA-GFP construct. At least 70% reduction in RFP signal in GFP-positive cells confirms on-target activity — a more direct functional readout than transcript-level qPCR. Polyclonal stable lines can be generated by antibiotic selection within 10 days, preserving parental cell heterogeneity compared to single-clone CRISPR approaches.